Video
Author(s):
Expert Michael Atkins, MD, reviews data from the ongoing IGNYTE study utilizing RP1 in combination with nivolumab in relapsed/refractory melanoma.
AI Support Tool Demonstrates Detection Utility for Melanoma at Primary Care Practices
FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma
Fox Chase Researcher Mitchell Fane Awarded $255,000 Grant to Explore Relationship Between Aging and Melanoma
CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice
Adjuvant Multipeptide Vaccine Combination Prolongs Survival in Melanoma
Immunogenomics Demonstrate Predictive Capability to Immunotherapy Resistance in Uveal Melanoma
Asciminib Bests Standard-of-Care TKIs in Ph+ CML
Lorlatinib Yields Longest Reported PFS in Advanced NSCLC
Rivoceranib Plus Camrelizumab Maintains Frontline Survival Benefit in Unresectable HCC
Dr Pal Previews ASCO 2024 Data in Renal Cell Carcinoma